Fundraising FoxOrphoMed
Mill Valley, US · Founded 2015 · Delaware corporation · 4 known investors
Find your way into OrphoMed
Sign up to see every warm intro you have to OrphoMed
- Paths you didn't know you had: your email and LinkedIn already hold routes to the OrphoMed team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Clinical-stage biotech developing therapies for inadequately-controlled gastrointestinal disorders.
Founders & leadership
NS
Nikhilesh Singh, Ph.D.Director, President, Chief Executive Officer and Treasurer
Board
MC
Michael ChaoBoard director
TD
Thomas D. KileyBoard director
Investors · 4
New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M
How we know: funding news · press coverage · Not right? Tell us
Pappas Capitallisted by Pappas CapitalDurham
How we know: Pappas Capital's portfolio page · Not right? Tell us
Pappas CapitalreportedResearch Triangle Park · $100K – $6M
How we know: funding news · Not right? Tell us
Takeda VenturesreportedCambridge · $1M – $5M
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$24.6M disclosed across 2 rounds · 2015–2017
▶$21.8MraisedMay 2017 · 17 investors · BiotechnologyRule 506(b)
▶$21.8MraisedMay 2017 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth WidderDirector
- Art PappasDirector
- Frank TortiDirector
- Nikhilesh SinghExecutive Officer, Director
- Michael MartinDirector
- Offering amount
- $39.3M
- Amount sold
- $21.8M
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$2.8MraisedJan 2016 · 10 investors · BiotechnologyRule 506(b)
▶$2.8MraisedJan 2016 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael ChaoDirector
- Nikhilesh Singh, Ph.D.Executive Officer, Director
- Thomas D. KileyDirector
- Offering amount
- $2.8M
- Amount sold
- $2.8M
- First sale
- Jul 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does OrphoMed do?
- Clinical-stage biotech developing therapies for inadequately-controlled gastrointestinal disorders.
- Who are OrphoMed's investors?
- OrphoMed's investors include New Enterprise Associates (NEA), Pappas Capital, Pappas Capital, Takeda Ventures.
- How much funding has OrphoMed raised?
- OrphoMed has disclosed $24.6M raised across 2 rounds.
- Where is OrphoMed headquartered?
- OrphoMed is headquartered in Mill Valley, US.